Xencor Inc
XNCR10.030USD
+0.780+8.43%
收盘 09/18, 16:00（美东）报价延迟15分钟
715.11M总市值
亏损市盈率 TTM
关于 Xencor Inc 公司
Xencor, Inc. 是一家临床阶段的生物制药公司，致力于开发用于治疗癌症和其他严重疾病的工程抗体。采用其 XmAb 技术设计的 20 多种候选药物正在临床开发中，三种 XmAb 药物由合作伙伴销售。其 XmAb 工程技术可以对蛋白质结构进行微小改变，从而产生新的治疗作用机制。其全资开发的候选药物包括 Vudalimab、XmAb819、XmAb808 和 XmAb541。与合作伙伴共同开发的候选药物包括 Plamotamab。合作伙伴推进的候选药物包括 Xaluritamig (AMG 509)、ASP2138、JNJ-9401、JNJ-1493 和 Novartis XmAb 未公开的抗体候选药物。其处于临床开发中的细胞因子药物候选药物包括 fbalropendekin alfa (XmAb306/RG6323)、XmAb564 和 XmAb662。该公司其他临床阶段候选药物包括 Obexelimab、AIMab7195 (XmAb7195) 和 Xpro1595。Vudalimab 是一种针对 PD-1 和 CTLA-4 的双特异性抗体。
公司简介
公司代码XNCR
公司名称Xencor Inc
上市日期Dec 03, 2013
CEODr. Bassil I. Dahiyat, Ph.D.
员工数量250
证券类型Ordinary Share
年结日Dec 03
公司地址465 N. Halstead St.
城市PASADENA
上市交易所NASDAQ Global Market Consolidated
国家United States of America
邮编91107
电话16263055900
网址https://xencor.com/
公司代码XNCR
上市日期Dec 03, 2013
CEODr. Bassil I. Dahiyat, Ph.D.
公司高管
名称
名称/职务
职务
持股
持股变动
Dr. John R. Desjarlais, Ph.D.
Dr. John R. Desjarlais, Ph.D.
Executive Vice President - Research, Chief Scientific Officer
Executive Vice President - Research, Chief Scientific Officer
212.96K
+10.45%
Ms. Celia E. Eckert
Ms. Celia E. Eckert
Senior Vice President, General Counsel, Corporate Secretary
Senior Vice President, General Counsel, Corporate Secretary
50.68K
+47.02%
Mr. Bart Jan Cornelissen
Mr. Bart Jan Cornelissen
Senior Vice President, Chief Financial Officer
Senior Vice President, Chief Financial Officer
33.17K
-10.16%
Mr. Kurt A. Gustafson
Mr. Kurt A. Gustafson
Independent Director
Independent Director
14.20K
+305.17%
Mr. Todd E. Simpson
Mr. Todd E. Simpson
Independent Director
Independent Director
13.69K
--
Mr. Richard J. (Rich) Ranieri
Mr. Richard J. (Rich) Ranieri
Independent Director
Independent Director
13.20K
+427.04%
Dr. Kevin C. Gorman, Ph.D.
Dr. Kevin C. Gorman, Ph.D.
Independent Director
Independent Director
--
--
Dr. Bassil I. Dahiyat, Ph.D.
Dr. Bassil I. Dahiyat, Ph.D.
President, Chief Executive Officer, Founder and Director
President, Chief Executive Officer, Founder and Director
--
--
Dr. A. Bruce Montgomery, M.D.
Dr. A. Bruce Montgomery, M.D.
Lead Independent Director
Lead Independent Director
--
--
Dr. Ellen Gwen Feigal, M.D.
Dr. Ellen Gwen Feigal, M.D.
Independent Director
Independent Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. John R. Desjarlais, Ph.D.
Dr. John R. Desjarlais, Ph.D.
Executive Vice President - Research, Chief Scientific Officer
Executive Vice President - Research, Chief Scientific Officer
212.96K
+10.45%
Ms. Celia E. Eckert
Ms. Celia E. Eckert
Senior Vice President, General Counsel, Corporate Secretary
Senior Vice President, General Counsel, Corporate Secretary
50.68K
+47.02%
Mr. Bart Jan Cornelissen
Mr. Bart Jan Cornelissen
Senior Vice President, Chief Financial Officer
Senior Vice President, Chief Financial Officer
33.17K
-10.16%
Mr. Kurt A. Gustafson
Mr. Kurt A. Gustafson
Independent Director
Independent Director
14.20K
+305.17%
Mr. Todd E. Simpson
Mr. Todd E. Simpson
Independent Director
Independent Director
13.69K
--
Mr. Richard J. (Rich) Ranieri
Mr. Richard J. (Rich) Ranieri
Independent Director
Independent Director
13.20K
+427.04%
收入明细
单位: USD更新时间: 7月6日 周日
单位: USD更新时间: 7月6日 周日
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
业务USD
名称
营收
占比
Royalties
18.23M
55.70%
Milestone
14.50M
44.30%
暂无数据
业务
地区
业务USD
名称
营收
占比
Royalties
18.23M
55.70%
Milestone
14.50M
44.30%
股东统计
更新时间: 8月23日 周六
更新时间: 8月23日 周六
持股股东
股东类型
持股股东
持股股东
占比
BlackRock Institutional Trust Company, N.A.
14.97%
PRIMECAP Management Company
14.76%
The Vanguard Group, Inc.
12.07%
EcoR1 Capital, LLC
8.62%
State Street Global Advisors (US)
5.35%
其他
44.23%
持股股东
持股股东
占比
BlackRock Institutional Trust Company, N.A.
14.97%
PRIMECAP Management Company
14.76%
The Vanguard Group, Inc.
12.07%
EcoR1 Capital, LLC
8.62%
State Street Global Advisors (US)
5.35%
其他
44.23%
股东类型
持股股东
占比
Investment Advisor
60.46%
Investment Advisor/Hedge Fund
30.38%
Hedge Fund
15.73%
Research Firm
3.76%
Venture Capital
2.85%
Individual Investor
1.31%
Pension Fund
1.03%
Bank and Trust
0.39%
Sovereign Wealth Fund
0.08%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
437
81.68M
114.52%
-1.81M
2025Q1
459
80.70M
113.40%
-3.00M
2024Q4
454
76.54M
108.64%
-2.55M
2024Q3
455
73.66M
105.55%
+3.66M
2024Q2
436
65.64M
106.20%
-4.06M
2024Q1
431
66.91M
108.52%
-498.74K
2023Q4
420
65.39M
107.20%
-1.62M
2023Q3
417
65.14M
107.37%
-1.33M
2023Q2
422
64.91M
107.12%
-2.55M
2023Q1
418
65.89M
109.12%
+515.07K
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
BlackRock Institutional Trust Company, N.A.
10.74M
15.09%
-230.83K
-2.10%
Mar 31, 2025
PRIMECAP Management Company
9.76M
13.71%
+776.58K
+8.64%
Mar 31, 2025
The Vanguard Group, Inc.
7.88M
11.08%
-118.90K
-1.49%
Mar 31, 2025
EcoR1 Capital, LLC
6.14M
8.63%
--
--
Mar 31, 2025
State Street Global Advisors (US)
3.68M
5.18%
+482.80K
+15.08%
Mar 31, 2025
T. Rowe Price Associates, Inc.
3.83M
5.38%
-108.25K
-2.75%
Mar 31, 2025
BVF Partners L.P.
2.74M
3.85%
+451.38K
+19.72%
Mar 31, 2025
TCG Crossover Management, LLC
2.45M
3.45%
--
--
Mar 31, 2025
RTW Investments L.P.
2.40M
3.38%
--
--
Mar 31, 2025
Dimensional Fund Advisors, L.P.
1.74M
2.44%
+235.86K
+15.71%
Mar 31, 2025
查看更多
持股ETF
更新时间: 9月2日 周二
更新时间: 9月2日 周二
机构名称
占比
iShares Genomics Immunology and Healthcare ETF
1.36%
Virtus LifeSci Biotech Clinical Trials ETF
1.04%
Invesco NASDAQ Future Gen 200 ETF
0.47%
Invesco S&P SmallCap Health Care ETF
0.4%
ALPS Medical Breakthroughs ETF
0.36%
Inspire Small/Mid Cap ESG ETF
0.21%
SPDR S&P Biotech ETF
0.19%
Direxion Daily S&P Biotech Bull 3X Shares
0.12%
SPDR SSGA US Small Cap Low Volatility Index ETF
0.08%
Avantis US Small Cap Equity ETF
0.07%
查看更多
iShares Genomics Immunology and Healthcare ETF
占比1.36%
Virtus LifeSci Biotech Clinical Trials ETF
占比1.04%
Invesco NASDAQ Future Gen 200 ETF
占比0.47%
Invesco S&P SmallCap Health Care ETF
占比0.4%
ALPS Medical Breakthroughs ETF
占比0.36%
Inspire Small/Mid Cap ESG ETF
占比0.21%
SPDR S&P Biotech ETF
占比0.19%
Direxion Daily S&P Biotech Bull 3X Shares
占比0.12%
SPDR SSGA US Small Cap Low Volatility Index ETF
占比0.08%
Avantis US Small Cap Equity ETF
占比0.07%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
